

# Resource Summary Report

Generated by ASWG on Aug 9, 2026

## Brilliant Violet 421(TM) anti-human CD38

RRID:AB\_2566230

Type: Antibody

---

### Proper Citation

BioLegend Cat# 356617, RRID:AB\_2566230

---

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_2566230](http://antibodyregistry.org/AB_2566230)

**Proper Citation:** BioLegend Cat# 356617, RRID:AB\_2566230

**Target Antigen:** CD38

**Host Organism:** mouse

**Clonality:** monoclonal

**Comments:** Applications: FC

**Antibody Name:** Brilliant Violet 421(TM) anti-human CD38

**Description:** This monoclonal targets CD38

**Target Organism:** human

**Clone ID:** Clone HB-7

**Antibody ID:** AB\_2566230

**Vendor:** BioLegend

**Catalog Number:** 356617

**Alternative Catalog Numbers:** 356618

**Record Creation Time:** 20250820T070106+0000

**Record Last Update:** 20250821T012526+0000

---

### Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 421(TM) anti-human CD38.

No alerts have been found for Brilliant Violet 421(TM) anti-human CD38.

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 2 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [ASWG](#) .

Cillo AR, et al. (2024) Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8+ T cells to promote antitumor immunity. *Cell*, 187(16), 4373.

Veatch JR, et al. (2022) Neoantigen-specific CD4+ T cells in human melanoma have diverse differentiation states and correlate with CD8+ T cell, macrophage, and B cell function. *Cancer cell*, 40(4), 393.